UNCLASSIFIED 

1

DEA-PHL-DIR-003-21 November 2020

Illicit Opioid Availability in 

Pennsylvania, 2020 

DEA 

Intelligence 

Report
UNCLASSIFIED

2

Executive Summary 

The Drug Enforcement Administration (DEA) Philadelphia Field Division (PFD) analyzed intelligence 

and investigative trends, as well as various data indicators, to assess the current illicit opioid 

availability threat in Pennsylvania. The analysis revealed an increasing illicit opioid availability 

in Pennsylvania between 2017 and 2019, showing that it remains among Pennsylvania’s most 

dangerous drug threats, and as demonstrated by the following key findings: 

• Law enforcement seized illicit opioids in nearly all Pennsylvania counties; illicit opioids 

comprised the highest percentage of seized/analyzed drugs. 

• The total weight of heroin seized by the DEA in Pennsylvania more than doubled, although the 

number of seizure incidents remained unchanged. 

• Users generally rejected poor-quality illicit opioid products: more than half of the retail quantity 

heroin seizures in Pennsylvania exceeded 50 percent purity, while most of the highest purity 

fentanyl exhibits were seized in retail quantities. 

• The illicit opioid supply in Pennsylvania shifted to fentanyl once Mexican transnational criminal 

organizations (TCOs) and Pennsylvania-based distributors realized fentanyl’s dramatically 

increased profit potential. 

• The DEA reported significant increases in the number of fentanyl seizures, wholesale quantity 

fentanyl seizures, total weight of fentanyl seized, and average weight of seized fentanyl in 

Pennsylvania. 

• The total weight of fentanyl-laced tablet (counterfeit controlled prescription drugs) seizures 

in Pennsylvania increased by 200 percent, with individual seizures containing up to 40,000 

tablets. 

• The most frequently identified fentanyl-related compounds in Pennsylvania were acetyl 

fentanyl, fluoroisobutyrl fentanyl, and furanyl fentanyl, while 3-methylfentanyl and carfentanil 

were consistently present. 

• Toxicology tests of fatal overdose victims revealed the true impact of illicit opioids in 

Pennsylvania, with fentanyl presence increasing dramatically since 2014-15. 

Details 

The increasing availability of illicit opioids is the most significant drug threat in Pennsylvania. The 

PFD monitors this threat closely, periodically reviewing multiple data indicators, in conjunction 

with investigative information, to continually assess the threat, then share analytical findings 

with stakeholders in federal, state, and municipal governments. In 2018, the PFD published 

The Opioid Threat in Pennsylvania which assessed the supply, demand, and abuse of opioids 

in the Commonwealth through 2016. This product updates current availability of illicit opioids in 

Pennsylvania based on 2017-2019 data, as the diversity and volume of supply evolved rapidly and 

prolonged an epidemic. 

Illicit opioids, to include heroin, fentanyl, and fentanyl-related compounds (FRC) sourced from 

Mexican and Chinese suppliers, remain a pervasive drug threat in Pennsylvania, where PFD 

offices, state/local law enforcement agencies, and other stakeholders report persistent increases in 

various indicators that demonstrate availability, such as the volume of illicit opioid seizures by law 

enforcement, identification of seized drugs as illicit opioids by laboratory analysis, and drug-related 
UNCLASSIFIED

3

(U) Figure 1. Seized and Analyzed Drug Exhibits by Group (Excerpted), Pennsylvania, 2017-2019 

Source: National Forensic Laboratory Information System

overdose deaths. According to information identified from numerous investigations, the production 

locations, trafficking methods and routes, and local distribution organizations remain consistent with 

previous reporting. However, the increase in heroin and fentanyl availability as measured by seizures 

and overdose deaths, the impact of evolving heroin and fentanyl purity, and the introduction of myriad 

FRCs into Pennsylvania’s illicit drug market since 2017 are the most significant findings resulting from 

this analysis. 

Data from laboratory-analyzed drug seizure exhibits, housed in the National Forensic Laboratory 

Information System (NFLIS), is a reliable indicator of existing and emerging trends in drug availability.a

 

Analysis of NFLIS data for drug seizure exhibits revealed that illicit opioids comprised nearly thirty 

percent of seized and analyzed drugs in Pennsylvania in 2019 (see Figure 1), and were seized in 97 

percent of Pennsylvania counties between 2017 and 2019 (see Figure 2).b

a. The DEA NFLIS collects results from drug chemistry analyses conducted by state, local, and federal forensic laboratories across 

the country. NFLIS provides analytical results of drugs seized by law enforcement and is a source of information for monitoring 

drug trafficking and availability in the United States. 

b. Montgomery and Bucks counties had seizures of illicit opioids, but were not included in the map due to incomplete data (see 

Footnote c). 
UNCLASSIFIED

4

Source: National Forensic Laboratory Information System 

(U) Figure 3. Heroin Seized by DEA in Pennsylvania, 2017-2019 

Source: DEA Philadelphia Field Division

(U) Figure 2. Number of Analyzed Illicit Opioid Exhibits by Pennsylvania County, 2017-2019c

Heroin Availability 

Heroin availability remains high in Pennsylvania, where the PFD observed a more than 200 percent 

increase in the number of wholesale quantity (one kilogram or more) seizures between 2018 and 

2019, resulting in a concurrent increase in the average weight of heroin seized per incident. Thus, 

while the number of DEA heroin seizures in Pennsylvania remained relatively stable from 2017 to 

2019, the total weight of heroin seized more than doubled (see Figure 3). 

c. Montgomery and Bucks counties use a private laboratory for drug chemistry analysis - this data is not included in NFLIS at this 

time. The lack of reported data herein does not indicate a lack of presence of these drugs in those counties. 
UNCLASSIFIED

5

Figure 4 shows more than six kilograms of wholesalepackaged unadulterated heroin supplied by Mexican 

sources and seized from a Philadelphia residence 

in 2019. 

Heroin Combinations 

At the time of importation into the United States, 

wholesale quantities of heroin rarely contain other 

controlled substances. This trend continues once 

wholesale quantities of heroin arrive in Pennsylvania, as 

laboratory analysis revealed that no additional controlled 

substances were identified in more than 80 percent of 

DEA heroin seizures between one and five kilograms, 

and in all heroin seizures greater than five kilograms in 

Pennsylvania between 2017 and 2019. 

Distribution organizations in Pennsylvania typically maximize their profit by cutting, i.e., mixing 

other controlled substances and/or other adulterantsd or diluentse

 with the primary illicit controlled 

substance to increase the volume of product packaged for street-level retail sale. For example, a 

kilogram of heroin can be purchased in Philadelphia for approximately $60,000, which represents 

a potential profit of about $42,000 per kilogram to the foreign source of supply. Regional and local 

distribution organizations then repackage that kilogram into approximately 50,000 bags for street sale 

(without further cutting) at about $10 per bag, generating more than $500,000 in sales. Historically, 

regional and local distributors mixed heroin with adulterants such as caffeine, procaine, quinine, and 

lidocaine to increase their profits, but sacrificed some quality of the final product for users. However, 

as noted below, users in Pennsylvania demand and can easily recognize a better quality, higher purity 

product; therefore, excessive diluting can negatively impact retail sales. 

The emergence of fentanyl in 2013 allowed distributors to “cut” or mix it with heroin, and enabled 

them to increase profits without sacrificing product quality. Such mixing continues, as confirmed 

by investigative intelligence and laboratory analysis. Users report that it is increasingly difficult to 

find heroin at the retail level that has NOT been mixed with fentanyl. Concurrently, the presence of 

fentanyl found alone (without other controlled substances) continues to increase (see Figure 5). As 

traffickers recognized, then sought to maximize, the increased profit potential of fentanyl over heroin 

(discussed in the Fentanyl section), the illicit opioid market in Pennsylvania shifted gradually to 

fentanyl. 

Further illustrating increased mixing of heroin with other controlled substances at the retail level 

in Pennsylvania, laboratory analysis revealed that more than 90 percent of retail heroin exhibits 

contained at least one additional controlled substance in 2019 (compared to less than half in 2017). 

Among these combinations, heroin was most frequently mixed with fentanyl or FRCs; however, 

tramadol recently emerged as a popular adulterant in street-level seizures.

d. An adulterant is a pharmacologically active substance that is added to heroin to enhance or mimic the effect of heroin. 

Adulterants can be added to heroin shipments immediately after production, in transit, or prior to distribution. 

e. A diluent is an inert ingredient (pharmacologically inactive compound) used to increase the bulk of a finished product. Typical 

diluents are sugars, starches, and inorganic salts. 

(U) Figure 4. Heroin Kilograms Seized 

in Philadelphia, 2019 

Source: DEA Philadelphia Field Division 
UNCLASSIFIED

6

(U) Figure 5. Heroin and Fentanyl Seized and Analyzed Drug Exhibits, Philadelphia, 2017-2019 (Q2) 

Source: National Forensic Laboratory Information System 

(U) Figure 6. Heroin/Fentanyl Bags Packaged for Retail Sale, Philadelphia, 2018 

Source: DEA Philadelphia Field Division 

Figure 6 shows an example of mixing of substances at the retail level, with more than 15,000 bags of 

heroin and fentanyl mixed and packaged for sale in Philadelphia. 

Heroin Purity 

Heroin purity in Pennsylvania has been a hallmark of dubious distinction, historically ranked among 

the highest in the country. A review of quantitated laboratory analyzed exhibits found that all of DEA’s 

wholesale heroin seizures in Pennsylvania between 2017 and 2019 exceeded 90 percent purity, 

indicating that wholesale quantities were not mixed with adulterants or diluents. Notably, more than 

half of the retail quantity (<1-50 grams) heroin seizures in Pennsylvania, whether already packaged or 

awaiting packaging for retail sale, were found with purities exceeding 50 percent. This data confirms 

anecdotal reporting that low-quality heroin is rejected in the user market; therefore, local distributors 

must limit diluents that solely increase the volume of product. User demand for highly potent illicit 

opioids, combined with the prospect of increased profits for Mexican sources of supply, facilitated 

the emergence and increasing presence of fentanyl in Pennsylvania’s illicit drug supply beginning 

in 2013.
UNCLASSIFIED

7

(U) Figure 7. Fentanyl Seized by DEA in Pennsylvania, 2017-2019 

(U) Figure 8. Ten Kilograms of Fentanyl Seized

 in Pennsylvania, 2019 

Source: DEA Philadelphia Field Division 

Source: DEA Philadelphia Field Division 

Fentanyl Availability 

Fentanyl is approximately 50 times stronger than heroin; therefore, significant increases in fentanyl 

availability pose an even greater danger to users. Since its emergence in 2013, fentanyl availability 

surged in Pennsylvania, clearly demonstrated by increases in the total weight of DEA seizures, the 

number of wholesale quantity seizures, and the average weight of fentanyl per seizure. Specifically, 

the PFD reported a more than 60 percent increase in the number of fentanyl seizures (regardless of 

weight) and a more than 130 percent increase in the total weight of fentanyl seized in Pennsylvania 

between 2017 and 2019, while the number of DEA wholesale fentanyl seizures in Pennsylvania 

increased more than 300 percent and the average weight per seizure rose to nearly 500 grams 

(see Figure 7). 

Figure 8 shows more than ten kilograms of 

fentanyl (sourced directly from Mexico) seized 

pursuant to a Pennsylvania traffic stop in 2019. 

Similar to heroin, wholesale quantities of 

fentanyl are not often adulterated with other 

controlled substances prior to smuggling 

into the United States and shipment to 

Pennsylvania. Laboratory analysis revealed 

that no additional controlled substances 

were identified in more than 70 percent of 

DEA fentanyl seizures between one and five 

kilograms, and in 100 percent of fentanyl 

seizures greater than five kilograms in 

Pennsylvania. 

Fentanyl profits, especially for foreign sources of supply, are higher than heroin profits due to lower 

costs and relative ease of production. Similar to heroin, local distributors repackage fentanyl for 

retail distribution; however, due to its extreme potency, fentanyl must be cut with other substances. 

A kilogram of fentanyl purchased from a source in Mexico can be cut into multiple kilograms locally 
UNCLASSIFIED

8

(U) Figure 9. Percentage of DEA 

Fentanyl Seizures in Pennsylvania by 

Purity Band, 2017-2019 

Source: DEA Philadelphia Field Division 

to increase the quantity of product available for retail sale, which increases profits dramatically 

throughout the local distribution chain. The availability of fentanyl allows retail distributors to offer 

a high-quality fentanyl-based product to users at or below the cost of a lesser quality heroin-based 

product, yet realize a higher profit. Using the example noted in the Heroin section earlier, a kilogram 

of fentanyl, once cut, can result in 250,000 bags packaged for retail sale, thereby increasing profits 

to more than $2.5 million. With well-established heroin demand, user markets, and distribution 

infrastructure in Pennsylvania, introducing fentanyl into the illicit supply presented a lucrative 

opportunity to Mexican traffickers. 

Fentanyl Purity 

The purity of fentanyl shipped from China commonly tests above 90 percent, with DEA reporting 

indicating that, in addition to producing fentanyl within Mexico, Mexican traffickers order fentanyl from 

China, cut it, and smuggle it into the United States. These methods account for the lower purities 

(averaging less than 10 percent pure) commonly associated with Mexican-sourced fentanyl. 

The purity of Mexican-supplied fentanyl, as measured in content by weight, is lower than heroin due 

to the increased potency of fentanyl. For example, one kilogram of fentanyl product smuggled into 

the United States actually contains a small amount of fentanyl (less than 10 percent) mixed with other 

substances, whereas one kilogram of heroin product contains a far greater portion of heroin. For the 

same reason, a quantity of fentanyl sold at the retail level presents a higher risk to the user than the 

same quantity of heroin. 

An analysis of fentanyl purity from DEA seizures in 

Pennsylvania shows significantly increasing percentages 

of higher-purity seizures (between five and ten percent), 

regardless of weight, from 2017 to 2019 (see Figure 9). 

Furthermore, and of greater concern, nearly all of the 2019 

analyzed exhibits that exceeded 10 percent purity were 

seized in quantities of less than 50 grams (not wholesale 

quantities). This is a clear indicator of a dangerous and 

increasingly potent fentanyl product available to users 

throughout the Commonwealth. 

Fentanyl-Laced Tablets 

Fentanyl is primarily seized in powder form in Pennsylvania; however, since 2016, laboratory analysis 

increasingly discovered fentanyl in counterfeit controlled prescription drugs (CPDs) available in the 

local drug supply. For example, PFD investigators seized more than 20,000 counterfeit oxycodone 

pills from a Philadelphia residence in October 2018. The tablets, similar to those shown in Figure 10, 

appeared as authentic oxycodone tablets, but laboratory analysis confirmed the presence of fentanyl. 

Counterfeit pill sources include Mexican TCOs, which produced and smuggled millions of counterfeit 

pills into the United States in the last few years, as well as local production operations that are 

occasionally encountered and dismantled by authorities. The PFD recently published a report entitled 

Counterfeit Controlled Prescription Drug Availability in Pennsylvania and Delaware which provides 

detailed analysis of this emerging trend and threat. 

Fentanyl-laced tablets (counterfeit CPDs) comprised more than 10 percent of the total weight of 

DEA’s fentanyl seizures in Pennsylvania during 2019 (compared to .05 percent in 2018). Also during 
UNCLASSIFIED

9

U) Figure 10. Comparison of Counterfeit Pills to Authentic Oxycodone 30mg Pills 

Source: DEA Philadelphia Field Division

Authentic Oxycodone 30mg Pill Seized Counterfeit Oxycodone 30mg Pills 

2019, PFD investigations yielded individual seizures ranging from 100 to 40,000 tablets of counterfeit 

CPDs containing fentanyl. Analysis of NFLIS data also shows the percentage of tablet exhibits 

containing fentanyl that were seized by law enforcement in Pennsylvania grew from 2017 to 2019. In 

addition, the number of Pennsylvania counties reporting such seizures grew concurrently (from 12 

in 2017 to 20 in 2019), further illustrating the increased availability of these new products in the illicit 

drug supply. 

Fentanyl-related Compound Availability 

Fentanyl-related compounds are in the fentanyl chemical family, with often similar pharmacological 

effects, yet minor variations in chemical structure. FRCs emerged in the Pennsylvania illicit drug 

market shortly after fentanyl appeared in 2013. Some distributors sought to avert widespread 

attention to fentanyl by providing users with a high quality, potent product that sold as heroin or 

fentanyl. This potent product contained FRCs that may not have been federally or state controlled at 

the time. Most of these substances are not approved for use in humans; therefore, information about 

potency and lethal dosages are frequently unknown. 

FRCs were almost exclusively shipped from China and supplied through internet-based orders 

shipped via mail and parcel services; however, DEA investigations are identifying emerging source 

locations such as India, particularly since the Chinese government enacted controls over all FRCs in 

May 2019. Unlike fentanyl, Mexican TCOs do not appear to frequently produce FRCs clandestinely; 

rather TCOs generally acquire them in finished form from Chinese or other foreign sources to 

smuggle into the United States. Intelligence and laboratory analysis indicate that some FRCs enter 

the drug supply at the regional or local level, where they are mixed with other controlled or noncontrolled substances during packaging for retail sale. According to laboratory analysis, FRCs 

are frequently found with a higher than 90 percent purity, thus presenting a grave threat to mostly 

unsuspecting users. 

Analysis of NFLIS data showed 15 distinct FRCs seized in Pennsylvania between 2017 and 2019. 

Overall, the most frequently identified FRCs were acetyl fentanyl, fluoroisobutyrl fentanyl, and 

furanyl fentanyl. A closer look at individual FRCs show that furanyl fentanyl was the most frequently 

identified FRC in 2017, but decreased considerably in 2019. Conversely, valeryl fentanyl was noted 

minimally in 2017, but was the second most frequently identified in 2019. The extremely potent FRC 

carfentanil was first identified in Pennsylvania during 2016 and has since remained present.f 

f. Carfentanil is a Schedule II opioid used for large animals and is 100 times more potent than fentanyl.
UNCLASSIFIED

10

(U) Figure 11. Fentanyl-related Compound Analyzed Exhibits, Pennsylvania, 2017-2019 (Q2) 

Source: National Forensic Laboratory Information System 

Source: National Forensic Laboratory Information System

Figure 11 shows the presence of individual FRCs each quarter, with the length of the bar indicating 

the volume of analyzed exhibits; only 5 of the 15 distinct FRCs were present throughout the reviewed 

period: 3-methylfentanyl, acetyl fentanyl, carfentanil, fluoroisobutyrl fentanyl, and furanyl fentanyl. 

Authorities seized FRCs in 63 of Pennsylvania’s 67 counties during the 2017-2019 period.g Figure 12 

shows the volume of analyzed exhibits by color, concentrated primarily in the Philadelphia, Pittsburgh, 

and Harrisburg/Lancaster/York metropolitan areas, while also showing the variety of FRCs found in 

each county by number. Notably, Allegheny and Philadelphia counties reported 15 and 13 distinct 

FRCs, respectively, during the analyzed time period. This is a strong indicator of evolving diversity 

in the illicit opioid drug supply in Pennsylvania’s two largest distribution markets and primary source 

areas for the rest of the Commonwealth. 

(U) Figure 12. Number and Distinct Types of Fentanyl-related Compound Analyzed 

Exhibits by Pennsylvania County, 2017-2019h

g. Montgomery and Bucks counties had seizures of FRC, but were not included due to incomplete data (see Footnote h). 

h. Montgomery and Bucks counties use a private laboratory for drug chemistry analysis - this data is not included in NFLIS at this 

time. The lack of reported data herein does not indicate a lack of presence of these drugs in those counties. 
UNCLASSIFIED

11

(U) Figure 13. Counterfeit Oxycodone 

Pills Containing Carfentanil Seized in 

Western Pennsylvania, 2019 

Source: DEA Philadelphia Field Division 

DRUG 

CATEGORY 2014 2015 2016 2017 2018 2019 

FENTANYL 14% 27% 47% 67% 70% 75%

FRC 4% 5% 18% 23% 20%

HEROIN 52% 53% 43% 38% 35% 40%

73% 

14% 

30% 

Source: DEA Philadelphia Field Division 

Laboratory-analyzed FRCs in Pennsylvania were primarily 

seized in powder form, and often found in combination 

with other illicit opioids. Analysis of NFLIS data found 

that approximately 60 percent of FRC-positive exhibits 

contained fentanyl, while about 40 percent contained 

heroin. This further illustrates the adulteration of drugs 

occurring at the local level, as previously documented 

herein. 

Two PFD investigations exemplify this threat: first, PFD 

investigators, while investigating a Philadelphia-based 

distribution organization in 2019, seized more than 700 

grams of purported heroin from a Philadelphia residence; 

laboratory analysis subsequently confirmed the presence 

of valeryl fentanyl, fentanyl, and heroin in the seized powder. Second, demonstrating the evolution 

of FRC availability and forms, authorities seized counterfeit oxycodone tablets containing carfentanil 

in western Pennsylvania in 2019 (see Figure 13). The investigation revealed that local sources 

purchased the carfentanil tablets from Dark Web sources with virtual currency and then received 

them via mail/parcel delivery. 

Illicit Opioid-related Overdose Deaths 

The public impact of increasing illicit opioid availability in Pennsylvania is best observed through the 

inordinate number of overdose deaths occurring in recent years. Specifically, fentanyl’s emergence 

into Pennsylvania’s illicit drug supply was immediately confirmed by a sharp increase in fentanylrelated overdose deaths, first noted in 2014-15. Since then, fentanyl surpassed heroin as the primary 

drug found in toxicology tests of Pennsylvania’s overdose decedents, with rates climbing each year, 

further demonstrating increasing fentanyl availability coupled with fentanyl’s gradual supplanting of 

heroin in the user market (see Figure 14). 

(U) Figure 14. Presence of Illicit Opioids in Overdose Deaths, Pennsylvania, 2014-2019i

The presence of FRCs in overdose deaths increased significantly between 2016 and 2017 (similar 

to fentanyl) and maintained about a 20 percent presence between 2017 and 2019. The most 

potent FRC, carfentanil, was noted in more than 150 deaths between 2017 and 2019, peaking at 

approximately 100 related deaths in 2017. Carfentanil-related deaths were reported in more than 20 

Pennsylvania counties, but concentrated in western Pennsylvania (see Figure 15).

i. 2019 data is not finalized as of October 2020; data displayed includes 46 counties with finalized 2019 data. 
UNCLASSIFIED

12

Source: DEA Philadelphia Field Division 

(U) Figure 15. Carfentanil-related Overdose Deaths by Pennsylvania County, 2017-2019j

Outlook 

The trends and analytical findings documented herein show that illicit opioid availability will likely 

continue to evolve and remain the top drug threat to Pennsylvania for the foreseeable future. 

Insatiable demand for a high-quality opioid product is now satisfied primarily by fentanyl, which 

is more dangerous to users, yet more cost-effective for suppliers to produce, transport, and 

distribute. Mexican TCOs, supported by numerous distribution networks scattered throughout the 

Commonwealth, will persist in supplying a robust opioid market in Pennsylvania. This will potentially 

attract new and former users seeking a presumed “safe” method of ingestion by continuing to produce 

counterfeit CPDs containing fentanyl and FRCs. 

Mexican TCOs, supported by numerous distribution networks scattered throughout the 

Commonwealth, will persist in supplying a robust opioid market in Pennsylvania and potentially 

attract new or former users seeking a presumed “safe” method of ingestion by continuing to produce 

counterfeit CPDs containing fentanyl and FRCs. High demand that is met with a steadily increasing 

illicit opioid supply will ultimately result in consistent, if not increased, levels of fatal and non-fatal 

overdoses overall in Pennsylvania, as well as those specifically attributed to illicit opioids. Therefore, 

persistent vigilance of the illicit opioid threat is critical, and the PFD will continue monitoring it through 

data indicators and trends derived from its investigations.

j. Data was provided by Pennsylvania Coroners and Medical Examiners; however, it is possible that not all carfentanil death reports 

were received and therefore, the map may underrepresent the number of carfentanil-related deaths during the specified time 

period. 
(U) This product was prepared by the DEA Intelligence Program - Philadelphia Field Division. 

Comments and questions may be addressed to the Indicator Programs Section at: 

DEA.IntelligenceProducts@usdoj.gov. For media/press inquiries, call: (202) 307-7977. 

DFN-701-03--Destroy 2 years after issuance or when the DEA Intelligence Report is superseded or obsolete.

DEA PRB 10-05-20-32 
Additional Comments: 

Name of Organization: ____________________________________________________________________________ 

Point of Contact: _________________________________ Telephone Number: _______________________________ 

Email: _________________________________________________________________________________________ 

Overall satisfaction with DEA Product 

Readability/Understanding of DEA Product 

Value/Usefulness of NNP Product 

Report Increased my Understanding or 

Knowledge of the report subject 

Product Relevance to my agency’s mission 

How will you use this report? 

(Check all that apply) 

Policy Formulation Situational Awareness

Training Resource Allocation

Operational Planning 

Other 

Very 

Satisfied 

Somewhat 

Satisfied 

Neither 

Satisfied nor 

Dissatisfied 

Somewhat 

Dissatisfied 

Very 

Dissatisfied 

DEA Product #: DEA-_______________________________________________________________________ 

Title: ____________________________________________________________________________________ 

_________________________________________________________________________________________ 

DEA Intelligence Product 

Feedback Database

NNPP-027-15 

August 30, 2016